- Morepen Laboratories has secured a multi-year CDMO mandate valued at approximately ₹825 crore (USD 91 million) from a global pharmaceutical company.
- Supplies are expected to begin within the next four to five months, with execution scheduled through Q1 of the following financial year.
Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organisation (CDMO) mandate valued at approximately ₹825 crore (USD 91 million) from a global pharma company. The company stated that supplies under the agreement are expected to begin within four to five months, subject to operational and regulatory processes, with execution planned through Q1 of the following financial year.
The engagement represents one of the largest single CDMO mandates in the company’s history. Morepen said the agreement supports its strategy to expand its manufacturing footprint. Built on more than four decades of active pharmaceutical ingredient (API) manufacturing, the company’s CDMO platform enables collaboration with pharmaceutical companies through multi-year supply programs.
The company operates facilities accredited by USFDA, WHO-GMP, and EU authorities. It provides integrated development-to-commercial contract manufacturing capabilities, supporting scale-ups and long-duration supply frameworks. Morepen is also evaluating capacity enhancement and technology investments aligned with its CDMO opportunity pipeline.
“This mandate represents an important milestone in the evolution of Morepen’s manufacturing platform. It reflects the confidence global customers place in our quality systems, regulatory track record, and execution capabilities.”
Sushil Suri, Chairman & Managing Director
Kushal Suri, President – International Growth (API), added that the company drove the program end-to-end with technical, regulatory, and commercial scale-up, delivering a solution designed for quality, continuity, and scale.
